牛皮癣是一种复杂的疾病,显着影响患者生活质量(QOL)的慢性炎症性皮肤病,特别是在生殖器的情况下,钉,和头皮牛皮癣。Bimekizumab是白介素(IL)-17A和IL-17F的抑制剂,用于治疗牛皮癣。这项回顾性研究的目的是评估bimekizumab通过治疗生殖器的有效性,钉,和头皮病变与牛皮癣超过24周。该研究于2022年5月和2024年2月对52例接受bimekizumab治疗的银屑病患者进行。通过对生殖器(生殖器-PGA)0/1的医师全球评估(PGA)率的实现来评估bimekizumab的治疗效果,指甲(PGA-F),头皮专用PGA(ss-PGA),静态PGA(sPGA),以及第4、16和24周的皮肤病学生活质量指数(DLQI)。Bimekizumab治疗显着改善生殖器,钉,和牛皮癣的头皮病变。在第24周,生殖器-PGA0/1,PGA-F0/1,ss-PGA0/1的成功率为96.2%,66.7%,或93.9%,sPGA0/1或DLQI0/1为93.9%或83.3%,分别。Bimekizumab对生殖器有效,钉,和牛皮癣的头皮病变,难以治疗的病变,同时在现实世界的临床实践中提高了生活质量。
Psoriasis is a complex, chronic inflammatory skin disease that significantly impacts patients\' quality of life (QOL), especially in cases of genital, nail, and
scalp psoriasis. Bimekizumab is an inhibitor of interleukin (IL)-17A and IL-17F and used for the treatment of psoriasis. The aim of this retrospective study was to evaluate the effectiveness of bimekizumab through in treating genital, nail, and
scalp lesions with psoriasis over 24 weeks. The study was conducted from May 2022 and February 2024 on 52 psoriasis patients treated with bimekizumab. The therapeutic effects of bimekizumab were evaluated by the achievement of Physician\'s Global Assessment (PGA) rates of 0/1 on the genitals (genital-PGA), fingernails (PGA-F),
scalp-specific PGA (ss-PGA), static PGA (sPGA), and the Dermatology Life Quality Index (DLQI) at weeks 4, 16, and 24. Bimekizumab treatment significantly improved genital, nail, and
scalp lesions with psoriasis. At week 24, the achievement rate of genital-PGA 0/1, PGA-F 0/1, ss-PGA 0/1 was 96.2%, 66.7%, or 93.9%, and that of sPGA 0/1 or DLQI 0/1 was 93.9% or 83.3%, respectively. Bimekizumab was effective for genital, nail, and
scalp lesions with psoriasis, difficult-to-treat lesions, and simultaneously improved QOL in a real-world clinical practice.